| P50 | author | Jennifer H Gutzman | Q42325976 |
| P2093 | author name string | Jyoti J Watters | |
| | Linda A Schuler | |
| | Matthew D Schroeder | |
| | Debra E Rugowski | |
| P2860 | cites work | Functional characterization of the intermediate isoform of the human prolactin receptor | Q22010878 |
| | BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C | Q24532869 |
| | cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype | Q28137770 |
| | Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis | Q28201509 |
| | Extracellular signal-regulated kinase 1/2-mediated phosphorylation of JunD and FosB is required for okadaic acid-induced activator protein 1 activation | Q28292778 |
| | A cytoplasmic inhibitor of the JNK signal transduction pathway | Q28586970 |
| | The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation | Q29400446 |
| | AP-1 as a regulator of cell life and death | Q29616558 |
| | The regulation of AP-1 activity by mitogen-activated protein kinases | Q29620431 |
| | AP-1: a double-edged sword in tumorigenesis | Q30014831 |
| | A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. | Q33652314 |
| | Rapid activation of protein kinase C in isolated rat liver nuclei by prolactin, a known hepatic mitogen | Q33671938 |
| | Should prolactin be reconsidered as a therapeutic target in human breast cancer? | Q33690324 |
| | Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression | Q33949075 |
| | FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas | Q34179474 |
| | Jun, the oncoprotein. | Q34279331 |
| | The mammalian Jun proteins: redundancy and specificity. | Q34279339 |
| | AP-1 in mouse development and tumorigenesis | Q34279346 |
| | Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. | Q34279362 |
| | Promoter specificity and biological activity of tethered AP-1 dimers | Q34282536 |
| | Signaling pathways in mammary gland development. | Q34434909 |
| | Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice | Q34471721 |
| | The role of prolactin in mammary carcinoma | Q35067253 |
| | A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum | Q35200753 |
| | Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. | Q35923922 |
| | The association of breast mitogens with mammographic densities | Q36646178 |
| | Accessory elements, flanking DNA sequence, and promoter context play key roles in determining the efficacy of insulin and phorbol ester signaling through the malic enzyme and collagenase-1 AP-1 motifs | Q38288893 |
| | Prolactin-induced cell proliferation in PC12 cells depends on JNK but not ERK activation | Q38312340 |
| | Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells | Q38323749 |
| | Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance | Q38327743 |
| | c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins | Q38335918 |
| | Interaction of a bZip oligopeptide model with oligodeoxyribonucleotides modelling DNA binding sites. The effect of flanking sequences. | Q38340729 |
| | Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases | Q40017378 |
| | c-fos proto-oncogene regulation and function | Q40567648 |
| | Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. | Q40635267 |
| | c-Jun N-terminal kinase activation of activator protein-1 underlies homologous regulation of the gonadotropin-releasing hormone receptor gene in alpha T3-1 cells. | Q40670692 |
| | AP-1 blockade inhibits the growth of normal and malignant breast cells | Q40700814 |
| | Prolactin stimulates activation of c-jun N-terminal kinase (JNK). | Q40847193 |
| | Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype | Q40926125 |
| | Dominant-negative c-Jun NH2-terminal kinase 2 sensitizes renal inner medullary collecting duct cells to hypertonicity-induced lethality independent of organic osmolyte transport | Q41065579 |
| | Erythropoietin-dependent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of Jak2. | Q41334500 |
| | Mechanism of action of a dominant-negative mutant of c-Jun. | Q41483975 |
| | p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity | Q42807486 |
| | Molecular interpretation of ERK signal duration by immediate early gene products | Q42812329 |
| | Cell cycle promoting activity of JunB through cyclin A activation | Q42812587 |
| | Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway | Q43691664 |
| | Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways | Q44542433 |
| | Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun | Q44876378 |
| | PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. | Q52545721 |
| | Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women | Q56882445 |
| | Activation and inhibition of the AP-1 complex in human breast cancer cells | Q70992069 |
| | AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin | Q71070377 |
| | Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone. Resultant transcriptional activation of ATF-2 and CHOP, cytoskeletal re-organization and mitogenesis | Q73357698 |
| | Biological and clinical associations of c-jun activation in human breast cancer | Q73645110 |
| | Prolactin (PRL)-PRL receptor system increases cell proliferation involving JNK (c-Jun amino terminal kinase) and AP-1 activation: inhibition by glucocorticoids | Q73688138 |
| | AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets | Q73876722 |
| | Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members | Q74081695 |
| | PRL modulates cell cycle regulators in mammary tumor epithelial cells | Q77438791 |
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3064-3075 | |
| P577 | publication date | 2004-08-19 | |
| P1433 | published in | Molecular Endocrinology | Q3319475 |
| P1476 | title | Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells | |
| P478 | volume | 18 | |